Regeneron Pharmaceuticals Inc. suspended testing of its Covid-19 antibody drug in the sickest hospitalized patients because of a safety concern, the latest setback for antibody-drug trials in patients with the most advanced disease.

Regeneron said Friday it is pausing enrollment of hospitalized Covid-19 patients receiving mechanical ventilation or high-flow oxygen, after an independent monitoring committee observed “a potential safety signal and an unfavorable risk/benefit profile at this time.”

The…

This post first appeared on wsj.com

You May Also Like

Companies lobby to get their workers first in line for vaccine

Companies are jockeying to get their employees fast-tracked for coronavirus vaccine shots,…

Top Colleges for High-Paying Jobs in Law

Journal Reports: College Rankings Top Colleges for High-Paying Jobs in Accounting By…

Bubble burst: New Zealand suspends quarantine-free travel with Australia as Delta variant surges

SYDNEY — New Zealand will pause its quarantine-free travel arrangement with Australia…

Move over, Mars: Why the moons of Jupiter and Saturn may be key to finding alien life

In the hunt for life outside Earth, Mars is old news. “I…